Anesthesiology and Pulmonary Medicine
Subscribe to Anesthesiology and Pulmonary Medicine
View Sample

FREE Email Newsletter

Scripps Research scientists reveal key mechanism governing nicotine addiction

January 30, 2011 9:34 am | by EurekAlert | News | Comments

(Scripps Research Institute) Scientists from the Florida campus of the Scripps Research Institute have identified a pathway in the brain that regulates an individual's vulnerability to the addictive properties of nicotine. The findings suggest a new target for anti-smoking therapies.

Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets

January 28, 2011 5:32 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, Jan. 28, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nisoldipine Extended-release (ER) Tablets,...

Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer

January 27, 2011 1:33 pm | by Bio-Medicine.Org | News | Comments

BRIDGEWATER, N.J., Jan. 27, 2011 /- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) and its subsidiary, BiPar Sciences, today announced that a randomized Phase III trial evaluating iniparib* (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the...


Novalung and Medos Start Cooperation

January 27, 2011 6:32 am | by Bio-Medicine.Org | News | Comments

ANN ARBOR, Mich., Jan. 27, 2011 /- Following the acquisition of Medos Medizintechnik AG by the private equity fund Zukunftsfonds Heilbronn (" Future Fund of Heilbronn") the company will cooperate closely in the future with Novalung GmbH (Heilbronn, Germany), which is expected to...

2011 Louis-Jeantet Prize for Medicine

January 26, 2011 10:35 am | by EurekAlert | News | Comments

(European Molecular Biology Organization) The 2011 2011 Louis-Jeantet Prize for Medicine is awarded to the German biologist Stefan Jentsch, a director at the Max-Planck Institute of Biochemistry in Martinsried, and to the Norwegian neurobiologists Edvard and May-Britt Moser, director and...

The American Association for Cancer Research Hosts its 102nd Annual Meeting

January 25, 2011 8:32 am | by AACR | News | Comments

The deadline for media housing requests for the AACR 102nd Annual Meeting 2011 is Friday, Feb. 25. A limited number of rooms have been set aside for editors and reporters, and we cannot guarantee that housing will be available after that date.

If Hospitals Want a Competitive Advantage - Use Brain Monitors in Surgeries Requiring Sedation says Renowned Anesthesiologist

January 25, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

NEWPORT BEACH, Calif., Jan. 25, 2011 /- Every business needs a competitive advantage over its rivals. Some use a cost advantage; others use a differentiation advantage. Hospitals are not immune from the constant struggle to attract and retain patients and doctors. Dr. Barry Friedberg says...

Chopin's hallucinations were probably caused by epilepsy

January 25, 2011 3:34 am | by EurekAlert | News | Comments

(BMJ-British Medical Journal) The composer Frederic Chopin, who regularly hallucinated, probably had temporal lobe epilepsy throughout his short life, reveals research published online in Medical Humanities. Hallucinations typically feature in seizure disorders, they say.


Mylan Announces Caduet® Settlement Agreement

January 25, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, Jan. 25, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that it has entered into a settlement agreement with Pfizer Inc. resolving litigation related to Caduet® Tablets, 2.5 mg/10, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg,...

Study examines earlier use of heart pumps in growing group of heart failure patients

January 24, 2011 11:34 am | by EurekAlert | News | Comments

(University of Michigan Health System) The University of Michigan Cardiovascular Center and the University of Pittsburgh have been awarded $13.3 million to explore the potential benefits of heart devices for the large and growing group of Americans with heart failure. The NIH and...

Mylan's Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets

January 24, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, Jan. 24, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pantoprazole Sodium Delayed-release (DR)...

Survey Finds Patients Oppose Prescription Mandate for OTC Medicines Containing Pseudoephedrine

January 24, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Jan. 24, 2011 /PRNewswire-USNewswire/ -- More than 300 million Americans get the common cold, and up to 70 million get the flu annually. But for the 60 million people who also have asthma and allergies, a cold or flu can pose even greater risks. Together, these respiratory...

Anti-estrogen medication reduces risk of dying from lung cancer

January 23, 2011 9:32 pm | by EurekAlert | News | Comments

(Wiley-Blackwell) A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual's risk of death from lung cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study supports the hypothesis that...


HEPA filters reduce cardiovascular health risks associated with air pollution

January 21, 2011 8:34 am | by EurekAlert | News | Comments

(American Thoracic Society) Using inexpensive air filters may help reduce cardiovascular disease risk that results from exposure to air pollution, according to researchers from Canada, who studied healthy adults living in a small community in British Columbia where wood burning stoves are...

Awake despite anesthesia

January 20, 2011 12:34 pm | by EurekAlert | News | Comments

(Deutsches Aerzteblatt International) Unintended awareness during surgery is classified as an occasional complication of anesthesia (one to two in 1,000 patients) -- but being aware of things happening during the operation, and being able to recall them later, can leave a patient with...

Covidien Announces Launch of Puritan Bennett(TM) 520 Portable Ventilator in Europe

January 19, 2011 11:34 pm | by Covidien | News | Comments

New, easy-to-use mobile respiratory device provides ventilation option for patients transitioning from the hospital to the home BOULDER, Colo., Jan 20, 2011 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in mechanical...

NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump® and ResQPOD® CPR D...

January 19, 2011 8:35 am | by Bio-Medicine.Org | News | Comments

ROSEVILLE, Minn., Jan. 19, 2011 /- A combination of two devices could save the lives of thousands of cardiac arrest patients each year if implemented nationwide, suggests clinical trial results published in today's online edition of The Lancet. A significantly higher percentage of...

ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbineâ„¢ NDA

January 19, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Jan. 19, 2011 /- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) announced today that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011 for the review of the Exelbine (ANX-530) New Drug Application...

Bus and tram passengers warned to keep their germs to themselves

January 18, 2011 12:37 pm | by EurekAlert | News | Comments

(University of Nottingham) You are six times more likely to end up at the doctors with an acute respiratory infection if you have recently used a bus or tram -- but those who use buses or trams daily might well be somewhat protected compared with more occasional users.

Findings on pollution damage to human airways could yield new therapies

January 17, 2011 8:34 pm | by EurekAlert | News | Comments

(Duke University Medical Center) Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease. The scientists also discovered that the...

Financing Demonstrates Faith in Surgical Sleep Apnea Treatment

January 16, 2011 10:36 pm | by San Diego Business Journal | News | Comments

A San Diego device maker has put to bed more than $8 million of funding to test and develop a pacemakerlike device that could help some sleep apnea sufferers get relief without relying on air masks.

'A stark warning:' Smoking causes genetic damage within minutes after inhaling

January 15, 2011 5:36 pm | by EurekAlert | News | Comments

(American Chemical Society) In research described as "a stark warning" to those tempted to start smoking, scientists are reporting that cigarette smoke begins to cause genetic damage within minutes -- not years -- after inhalation into the lungs. Their report, the first human study to...

Dr. Peter J. Pronovost to Join the Board of Directors of Cantel Medical Corp.

January 13, 2011 7:36 am | by Bio-Medicine.Org | News | Comments

LITTLE FALLS, N.J., Jan. 13, 2011 /- Cantel Medical Corp. (NYSE: CMN ) today announced the election of Peter J. Pronovost, M.D., Ph.D. to serve as an independent member of Cantel's Board of Directors. "Dr. Pronovost is a world renowned leader of patient safety and quality, serving as a...

HASCO Medical Signs Agreement With the State of Alabama

January 13, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

MOBILE, Ala., Jan. 13, 2011 /- HASCO Medical, Inc. (OTC Bulletin Board: HASC ), , a managed healthcare provider that serves patients in Alabama, Florida, and Mississippi, today announced that Southern Medical & Mobility (SMM), a wholly owned subsidiary of HASCO...

K-V Pharmaceutical Company Updates Status of New Drug Application for Gestivaâ„¢

January 12, 2011 7:35 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, Jan. 12, 2011 /- K-V Pharmaceutical Company (NYSE:  KVa/KVb) today issued an update on the status of the U.S. Food and Drug Administration's review of Hologic, Inc.'s (Hologic) New Drug Application (NDA) for Gestiva™ (hydroxyprogesterone caproate injection) as a...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.